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Summary
Induction of HIV-1 broad neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development
but has remained challenging partially due to unusual traits of bnAbs, including high somatic
hypermutation (SHM) frequencies and in-frame insertions and deletions (indels). Here we
examined the propensity and functional requirement for indels within HIV-1 bnAbs. High-
throughput sequencing of the immunoglobulin (Ig) VHDJH genes in HIV-1 infected and
uninfected individuals revealed that the indel frequency was elevated among HIV-1-infected
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subjects, with no unique properties attributable to bnAb-producing individuals. This increased
indel occurrence depended only on the frequency of SHM point-mutations. Indel-encoded regions
were generally proximal to antigen binding sites. Additionally, reconstruction of a HIV-1 CD4-
binding site bnAb clonal lineage revealed that a large compound VHDJH indel was required for
bnAb activity. Thus, vaccine development should focus on designing regimens targeted at
sustained activation of bnAb lineages to achieve the required SHM and indel events.
Introduction
With the use of antigen-specific memory B cell isolation and antibody rescue techniques, a
large number of HIV-1 broad neutralizing antibodies (bnAbs) have been isolated(Haynes et
al., 2011). All bnAbs share one or more unusual traits such as autoreactivity, long heavy-
chain third complementarity-determining regions (HCDR3s), and high levels of somatic
hypermutation(Walker et al., 2011, Walker et al., 2009, Haynes et al., 2005, Haynes et al.,
2012, Kwong and Mascola, 2012, Mouquet and Nussenzweig, 2012, Wu et al., 2010, Wu et
al., 2011, Zhou et al., 2010, Mascola and Haynes, 2013, Liao et al., 2013) all traits that can
limit the induction of such antibodies(Haynes et al., 2005, Haynes et al., 2012, Mascola and
Haynes, 2013, Verkoczy et al., 2011).
Some recently isolated HIV-1 bnAbs have been noted to possess another unusual
characteristic: multibase in-frame insertions or deletions (indels)(Wu et al., 2010, Walker et
al., 2011). Indels are introduced during somatic hypermutation, and are thus found
exclusively in germinal center or post-germinal center B cells(Fukita et al., 1998). The
proportion of indels among somatic mutations in the normal human B cell repertoire is
small. Wilson et al examined IgG memory cells from human tonsil and reported 6 indels in
110,000 bases sequenced from productive genes, comprising both 3- and 6- base insertions
and deletions(Wilson et al., 1998). Using high-throughput sequencing, Briney et al(Briney et
al., 2012) found slightly higher frequencies of in-frame insertions (1.8% of all sequences)
and in-frame deletions (2.0-2.6% of all sequences) in FACS-sorted memory B cells. Smith
et al(Smith et al., 1996) studied unselected mutations in the introns between the JH and
constant region genes and found that 1-2% of all unselected somatic mutations were single-
base insertions or deletions. When indels do occur in normal B cells, they are usually short;
their frequency decreases rapidly with length (Wilson et al., 1998). Here we have surveyed
bnAb sequences, and found that 40% of reported HIV-1 bnAbs have indels, and that the
indel sizes cover the remarkable range from 3 to 33 nucleotides.
Because induction of bnAbs may be central to HIV-1 vaccine development efforts, it is of
great interest to determine why indels occur at such great frequency in bnAbs. There are
several hypotheses regarding the cause of this striking bias. Perhaps patients who produce
bnAbs have an underlying propensity to incorporate indels during affinity maturation.
Another possibility is that chronic HIV-1 infection induces the generation of indels, and that
indels will be found at greater frequencies in all HIV-1 infected patients. It is also possible
that there are genetic polymorphisms that affect the somatic hypermutation mechanism and
predispose carriers to produce high levels of somatic hypermutations and indels during the
induction of bnAbs. If genetic polymorphins are the cause for elevated SHMs, it would have
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serious consequences for the development of vaccines to elicit bnAbs, in that only those
with such a genetic background will be able to make vaccine-induced bnAbs. In addition it
is important to know if indels can be required for bnAb activity. To test these ideas, we
examined heavy chain sequences from HIV-1-infected individuals who make bnAbs, as well
as from HIV-1 infected individuals who do not. To determine the functional consequences
of insertion/deletion events, we made a detailed reconstruction of a VRC01-like CD4
binding site bnAb (CH31) clonal lineage and demonstrated that a large compound indel was
essential for both bnAb affinity maturation and HIV-1 neutralization.
Indels are found at high frequency among HIV-1 bnAbs
Many of the recently isolated bnAbs have been observed to have insertions or deletions. To
determine whether the occurrence of indels in bnAbs is disproportionally high, we examined
the reported 56 HIV-1 bnAb gene-pairs (Supplementary Table 1), that constituted 26 sets of
clonally-related heavy and light-chain genes. Among these genes we identified 27 unique in-
frame indels. Half of these indels were 3 nt long, but insertions as large as 33 nt and
deletions up to 15nt were also observed (Table 1). Overall, 40 of the 108 bnAb genes
contained indels. Counting unique indels only, the frequency of indels in this group of genes
was 27/108 (25%). This rate is nearly seven times higher than that observed in a collection
of ~13,000 human heavy chain variable regions downloaded from NCBI Genbank. Thus, the
frequency of indels among bnAbs is elevated.
To determine whether the high frequency of indels in bnAbs was attributable to an increase
in the frequency of indel-bearing antibodies generally in all chronically infected HIV-1
infected individuals, versus selective increase of indels in bnAb-producing individuals, we
determined the frequency of indels in unbiased samples of Ig variable-region genes from
blood B cells using Roche 454 high-throughput DNA sequencing (HTS) of full-length
genomic VHDJH rearrangements. We generated and analyzed HTS data comprising
3,778,439 sequencing reads from 261 samples taken at different times from 75 human
subjects. These individuals included 41 HIV-infected individuals (8 bnAb producers and 33
non-bnAb producers), 18 influenza-vaccinated individuals, and 16 HIV-1, uninfected
individuals (Supplementary Tables 2-3).
After discarding sequences rearranged out of frame or containing frame-shifting indels, we
analyzed a total of 3,352,720 sequences using statistical methods and software developed for
this purpose(Kepler, 2013). All alignments between sequencing reads and gene segments
used an affine gap scoring function(Gotoh, 1990). Each sequence was scored either as
containing or not containing an in-frame insertion and/or deletion.
We found that VHDJH genes from HIV-1-infected bnAb and non-bnAb subjects have higher
levels of indels than do those from healthy influenza-vaccinated and non-HIV-1-infected
groups (Fig. 1a,b). Compared to non-HIV-1 infected subjects, the geometric mean insertion
frequency was 27% higher in HIV-1 infected individuals (p = 0.03; ANOVA); the geometric
mean deletion frequency was similarly 23% higher in HIV-1 infected individuals (p = 0.03;
ANOVA). Importantly, with HIV-1 infected individuals, indel frequencies did not
significantly differ between bnAb-producing and - non-producing subjects (p > 0.1 in both
cases; Tukey multiple-comparisons test).
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Mean indel frequency is predicted by mean mutation frequency
The frequency of point mutations is similarly elevated in HIV-1 infected individuals
(ANOVA p < 0.01 for differences attributable to subject classification; Tukey multiple
comparisons, p < 0.05 for differences specific to HIV-1 status). This result raises the
possibility that both point-mutation and indel frequencies are increased together by the same
underlying cause. We hypothesized that since indels are induced by the same mechanism as
point-substitutions, a higher overall mutation level could account for the higher indel
frequency. To evaluate this possibility, we performed linear regressions of log average
insertion or deletion frequency against the log of the substitution frequency. The regressions
were performed with separate regression coefficients for each subject classification group as
well as with a common regression coefficient for all subjects. The regression coefficients
were not statistically different among subjects for either insertions or deletions (p > 0.1,
ANOVA; Figs. 1c, d); the estimate (± standard error) for the common regression coefficient
was 1.95±0.13 for insertions and 1.44±0.22 for deletions. Figure 1a and b also show the
residuals remaining after subtracting the insertion and deletion frequencies predicted using
the common-coefficient regression models, illustrating that most of the variability among
classifications was attributable to differences in point-substitution frequency.
We were able to study nine HIV-1 infected individuals (five among the bnAb-producers and
four among the non-bnAb producers) with VHDJH sequencing data from three or more
sampling times. The frequency of indel-containing sequences was variable over time (Fig.
2). Simple linear regression of insertion or deletion frequencies against days post-infection
found regression coefficients for insertion significantly greater than zero in 2/9 cases (p <
0.05) while8/9 regression coefficient estimates were positive, significantly more than
expected if there were no temporal trend (p = 0.004, two-sided sign test). No such trend was
evident for deletions—no correlation coefficients differed statistically from zero, and 4/9
were positive. Although indel frequency is volatile, there is a weak but detectable tendency
for insertions, but not deletions, to increase over time with HIV infection.
To address the question of whether chronic infections other than HIV are associated with
increased rates of insertions and deletions, we examined HTS heavy-chain Ig repertoire data
from subjects chronically infected with cytomegalovirus (CMV), Epstein-Barr virus (EBV),
both viruses, or neither(Wang et al., 2014). There were no detectable differences among
these groups in the rates of in-frame insertions or deletions (p > 0.1, ANOVA; Fig. S2).
Indel placement and antigen recognition
To determine whether indels in bnAbs were preferentially found in antigen-interacting
regions or were more randomly distributed, we analyzed a set of 11 antigen-bound bnAb
structures containing a total of 18 indels (Supplementary Methods). Fifteen of 18 (83%)
indels were found within 10 Å of the respective antigen binding site (Fig. 3). In comparison,
analysis of loop regions (assumed to be able to more easily accommodate indels due to
fewer structural constraints compared to beta strand regions) revealed that only ~1/3 of loop
residues were found within 10 Å of the respective antigen, even when removing potential
skewness due to over-representation of specific antibody classes (Fig. S1). The distributions
of the indel and loop residue locations were significantly different (p < 0.0001, Mann-
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Whitney test). These results indicated that while there was little constraint on the location
where indels can be accommodated, their presence related directly to antigen recognition.
One potential caveat of this analysis is that proximity to antigen was measured based on the
Env subunit antigen constructs in the available crystal structures, rather than a functional
HIV-1 spike, thus possibly underestimating the proximity to antigen for some indels.
Overall, indels were preferentially found in close proximity to antigen binding sites, and
thus likely improved, interactions with antigen.
The indel in VRC01-like CD4 binding site CH30-CH34 clonal lineage was required for bnAb
affinity maturation
We have recently reported the occurrence of two different sets of clonally-related bnAbs in
the same HIV-1 infected individual that together accounted for all of the plasma bnAb
activity(Wu et al., 2011, Bonsignori et al., 2012). This individual (CH0129) had both
VRC01-like CD4 binding site and V1V2 quaternary bnAb activity(Bonsignori et al.,
2012),(Bonsignori et al., 2011). The VRC01-like CD4 binding-site clone CH30-CH34
experienced indel formation, while the V1V2 PG9-like bnAb clonal lineage CH01-04 did
not. We reconstructed the corresponding CH31 clonal lineage using statistical inference on
the originally isolated genes, supplemented with targeted HTS reads to determine the
affinity maturation history and the role of indel in affinity maturation and acquisition of
neutralization breadth in the observed CH31 lineage CD4bs antibodies (Fig. 4, Table 2).
The members of the CH31 clonal lineage are similar to other VRC01-like bnAbs clone in
their use of the VH1-2*02 gene segment(Wu et al., 2011, Bonsignori et al., 2012).
Moreover, the crystal structure of CH31 complexed to gp120 is superimposable on that of
VRC01(Zhou et al., 2013). Most strikingly, perhaps, is the observation that both VRC03 (a
member of the VRC01 clonal lineage) and all the members of the CH31 clonal lineage
contain large indels. VRC03 has a 21 nt insertion in framework region 3. The CH31 clonal
lineage genes have a net 27 nt insertion within CDR1 that resolves into a 6 nt deletion and a
33 nt tandem duplication (Fig. 4a). Using HTS targeted at VHDJH genes rearranging to the
VH and JH gene segments used by CH31 lineage antibodies, we were able to isolate genes
situated close to the inferred unmutated common ancestor (UCA) on the clonal tree and
prior to the indels. Importantly, we isolated 14 unique VHDJH genes that were clearly
members of the CH31 clonal lineage, but did not have the indel, as well as isolated several
hundred more mutated VHDJH genes that did have the indel (Figure 4c).
The CH31 clonal lineage history demonstrated a striking accumulation of mutations in the
vicinity of the eventual indel, including the formation of an activation-induced cytidine
deaminase (AID) AGC hotspot that likely contributed to the genetic instability responsible
for the indel (Fig 4a). Indeed, a feature common to all of the bnAbs that have experienced
indels is an accumulation of point mutations on either side of the insertion or deletion (Fig.
S1).
We next expressed antibody members of the CH31 clonal lineage representative of key
stages along the maturation pathway as well as four artificial heavy chain constructs (Figs.
4b) that were intended to probe the specific contributions of the indel to the affinity, kinetic
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parameters, and neutralization capacity of CH31 bnAb lineage antibodies generated before
and after indel occurrence.
Consider the line of descent leading from the UCA to the mature antibodies CH30-CH34
(Fig. 4b). GNM7S is an observed heavy-chain sequence lying just off the line of descent. It
arose just before the indel was acquired, and is the indel-free sequence farthest from the
UCA. Among post-indel sequences, H162G is closest to the UCA along the line of descent.
GNM7S and H162G differ by 16 nucleotide substitutions in addition to the indel. The
differences between the two in terms of their biophysical properties are likely due both to
the indel and the nucleotide substitutions. To isolate the influence of the indel from the
influence of the simple substitutions, we designed and synthesized four heavy chains that
represent hybrids of antibodies H162G and GNM7S involving inclusion or removal of the
tandem duplication.
The relationships between the observed and synthetic sequences are shown schematically in
Fig. 4b. Each heavy chain sequence can be decomposed into three elements: the duplicated
element, or duplicon(Eichler, 1998), and the elements 5′ and 3′ respectively, of the duplicon.
The 5′ element is denoted A, the duplicon D, and the 3′ element B. The structure of GNM7S
is given by A0 D0 B and that of H162G is A1 D1 D2 B. The duplicons D0, D1, and D2 are
homologous 33-nucleotide tracts that differ from each other by 5-13 nucleotides. A0 and A1
differ from each other by 17 nucleotide substitutions and a 6 nucleotide deletion. GNM7S
and H162G share an identical B element. The following four antibody heavy chains were
synthesized by adding a duplicon to GNM7S (A1 D1 D0 B and A1 D0 D2 B) or deleting a
duplicon from H162G (A1 D1 B and A1 D2 B). Each artificial heavy chain was paired with
the light chain of a statistically-inferred post-insertion antibody for full antibody expression.
We estimated antibody binding kinetic parameters affected by the indel by surface plasmon
resonance (SPR) analysis of CH31 lineage members binding to HIV-1 AE.A244
gp120(Alam et al., 2013). Figure 5 shows that, in the natural CH31 lineage, the association
rate of lineage antibodies for AE.A244 gp120 binding increased and the dissociation rate
decreased with evolutionary distance (in expected number of mutations per base) from the
inferred UCA. The artificial antibody constructs in which an indel duplicon was inserted but
no other changes made showed that this single change brought about an 8-fold increase in
the association rate (Fig. 5a). When the indel duplicon was deleted from the post-indel
heavy chain, the association rate of the antibody for binding to AE.A244 gp120 decreased
by an order of magnitude (2H162G-D1, Fig. 5a). The dissociation rate was slightly
decreased by insertion of the duplicon from 2GNM7S to both 2GNM7S+D1 and 2GNM7S
+D2. Upon its deletion, however, the dissociation rate was increased 3-fold (2H162G-D1,
Fig.5b). No antibodies less diverged than 2JSKAU from the UCA showed binding of any
measurable degree to AE.A244 gp120 (not shown).
Broad Neutralization by CH31 antibody is acquired after indel formation
Finally, we assayed members of the CH31 clonal lineage for their ability to neutralize
heterologous HIV-1 strains in the TZBbl neutralization assay (Table 2). We found that
neutralization breadth did not arise until after the occurrence of the indel. The only tier 2
(difficult to neutralize) strain neutralized before the indel was A.Q23, with neutralization of
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other strains only acquired after the indel with antibodies 2H162G and 2H4HE representing
the point in the CH31 lineage with neutralization breadth.
Discussion
In this study, we have demonstrated the high frequency of indels among HIV-1 broad
neutralizing antibodies, showed that these indels occur predominantly near bnAb antigen
contact sites, and demonstrated an example of the requirement for an indel for affinity
maturation and bnAb activity in the VRC01-like CH31 bnAb lineage.
Not all HIV-1 infected individuals make bnAbs, although it has recently been shown that the
ability to make BnAbs is not dichotomous. That is, serum neutralization breadth is graded
among infected individuals(Hraber et al., 2014). What is not yet known is whether there are
host factors such as a genetic predisposition that are responsible for the differences there are.
Alternatively, there may be as-yet undetermined differences in the circumstances of the
infection itself, such as total antigenic variability or viral load that drives bnAb production.
On the other hand, there may be no host or pathogen factors that determine bnAb status.
Instead, bnAb status may be stochastic, driven essentially by the stochastic nature of B cell
affinity maturation itself. In this study we demonstrate that insertion and deletions occur at
unusually high frequencies among bnAbs and that the occurrence of indels in HIV-1 bnAbs
is determined by the degree of SHM that occurs in HIV-1 infection, rather than by the action
of factors specific to those patients that have detectable plasma bnAbs. By examining a total
of 3,352,720 genomic DNA sequencing reads from individuals with and without HIV-1
infection, we found that the rate of indels could be accounted for by a single mutation
frequency driving both point-substitution and indels in all groups, with only this single
mutation frequency varying among groups. Furthermore, the frequencies of both indels and
substitutions were only slightly higher in HIV-1 infected patients, and there was no
statistically significant difference between HIV-1 infected patients who have detectable
plasma bnAbs and those who did not. Moreover, we found that the indel frequency depends
on the substitution frequency raised to a power greater than one. Mathematically, the
relationship between the frequency of insertions or deletions f and the frequency of
substitutions μ is given by
(0.0)
where β > 1. The interpretation of this finding is that the excess SHM frequency of bnAbs is
sufficient by itself to account for the increase in indel frequency. Thus, high indel frequency
does not represent a separate class of bnAb anomaly and does not implicate unknown host
factors or genetic predisposition to generate bnAbs. In this regard, we have recently
performed full exon-sequencing on 50 bnAbs and 50 non-bnAbs HIV-1 infected individuals
and demonstrated no genome-wide gene maturation associated with the ability to make
bnAbs (Shea, P, Haynes, B, Goldstein, unpublished).
Previously, Krause et al(Krause et al., 2011) investigated the role of an insertion in a human
antibody against influenza HA by deleting the insert while leaving all other somatic
mutations intact and comparing binding affinities between the two forms of the antibody.
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They found that the removal of the insertion increased the equilibrium dissociation constant
35-fold, largely through increasing the kinetic dissociation rate. Pejchal et al(Pejchal et al.,
2011) deleted the inserts from two gp-120-binding anti-HIV-1 antibodies, while leaving the
rest of the molecules intact. They found that the binding affinity for the antigen, and their
ability to neutralize the virus, were diminished by the removal of the insert. Our goal and
our findings were different from these studies in an important way. While the previous
groups of investigators sought to determine the role of the insert in the function of the extant
antibodies, we sought to elucidate the role of the insertion event in the affinity maturation of
the bnAb clonal lineage. Thus, we isolated lineage members from before and after the
compound insertion/deletion event and produced four constructs that represent possible
intermediate forms. We found that after an insertion or deletion event, point-mutations
continue to accumulate in the context of the indel. These post-indel mutations may have
very different effects in the presence of the indel than they would in its absence. Removing
the insert from the mature antibody did not return the antibody to its pre-indel state because
the post-indel point mutations were still intact. Our studies more closely approximate the
history of the lineage at the time of the indel’s occurrence.
Our analyses demonstrate that insertions and deletions are prevalent at very high frequency
in bnAbs, that indels can be critical for bnAb activity, and that indel frequency increases
with and is predicted by the frequency of SHM-mediated substitution. The last point is
important because it suggests that the continued accumulation of point mutations in HIV-
infected individuals naturally leads to more substantial sequence alterations, such as
insertions and deletions, without additional genetic predispositions. It follows that a vaccine
strategy specifically designed to target and persistently activate bnAb precursors and their
descendants(Haynes et al., 2012) can induce the full spectrum of antibody somatic
hypermutations seen in bnAbs and may induce bnAbs as well.
Experimental Procedures
Human Samples—DNA samples prepared from a total of 261 peripheral blood
mononuclear cell (PBMC) samples from 75 human subjects for analysis of VHDJH by HTS.
These individuals included 41 HIV-infected individuals (8 bnAb producers and 33 non-
bnAb producers)(Shen et al., 2009, Tomaras et al., 2011, Morris et al., 2011, Moore et al.,
2011), 16 healthy, uninfected individuals, and 18 healthy individuals vaccinated with the
2007-2008 or 2008-2009 seasonal inactivated influenza vaccines as described(Moody et al.,
2011). Those characterized as bnAb producers either had broad neutralizing plasma
antibodies by previously described criteria from the CHAVI chronic HIV-1 infection
cohort(Tomaras et al., 2011) and/or had bnAbs isolated from blood B cells as
described(Shen et al., 2009, Morris et al., 2011). PBMC samples were used for DNA
isolation for HTS from the influenza vaccinated individuals taken before, 7 days and 21 days
after vaccination(Moody et al., 2011) using the methods as described previously(Wrammert
et al., 2008, Liao et al., 2009, Moody et al., 2011). All work related to human subjects was
in compliance with Institutional Review Board protocols approved by the Duke University
Health System Institutional Review Board.
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Inference of unmutated common ancestor (UCA) and identification of clone
members—The inference of the VHDJH and VLJL of the UCA and intermediate antibodies
of CD4BS bnAb VRC-CH30-34 clonal lineage is described in detail elsewhere(Kepler,
2013, Kepler et al., 2014). Briefly, we parameterize the VDJ rearrangement process in terms
of its gene segments, recombination points, and n-regions. Given any multiple sequence
alignment A for the set of clonally related genes and any tree T describing a purported
history, we compute the likelihood for all parameter values, and subsequently the posterior
probabilities on the rearrangement parameters conditional on A and T. We can then find the
UA with the greatest posterior probability and compute the maximum likelihood alignment
A* and tree T* given this UA, and then recompute the posterior probabilities on
rearrangement parameters conditional on A* and T*. We iterate the alternating conditional
optimizations until convergence is reached.
To infer likely clonal relatedness, we use the following statistical procedure. Two sequences
are regarded as potential relatives if they are inferred to have used the same IGHV and IGHJ
genes (without regard to allelic differences) and if the number of differences between the
two sequences in their CDR3 is not so large that the following hypothesis is rejected. The
hypothesis is that the two CDR3 evolved from a common precursor and that along each of
the two branches, the mutation frequency is as estimated from the count of point-mutations
in IGHV alone. The test itself is a z-test based on the Gaussian approximation to the
binomial.
Isolation of VHDJH and VL genes and expression of VHDJH and VLJL genes as
full-length IgG1 recombinant monoclonal antibodies (mAbs)—The VHDJH and
VLJL gene segment pairs were isolated by RT/PCR from sorted single plasma cells from
PBMC collected from healthy blood donors and from vaccinees 7 days after vaccination
with either the 2007-2008 or 2008-2009 inactivated influenza vaccine according to a
protocol approved by the Duke University Health System Institutional ReviewBoard(Moody
et al., 2011). The VHDJH and VLJL gene segment pairs of the observed VRC-CH30-34 were
obtained as described previously(Wu et al., 2011). Additional VHDJH were identified by
HTS(Wu et al., 2011, Boyd et al., 2009). Clonally related sequences derived from the
observed CH31-34 and from the cDNA HTS were combined and used to generate
maximum-likelihood phylogenetic trees (Fig 3c). The VHDJH_gene sequences identified by
HTS indicated in blue boxes in Figure 1c have been synthesized and paired with
intermediate-4 light chain for production of recombinant mAbs for testing the binding and
neutralizing activity using the method as described previously(Liao et al., 2011, Liao et al.,
2013).
Structural analysis—A set of 11 antigen-bound structures for the following indel-
containing bnAbs were included in the analysis: VRC01, VRC03, VRC-CH31, VRC-PG04,
NIH45-46, 3BNC117, VRC-PG20, CH103, PG9, PGT128, and PGT135(Wu et al., 2010,
Bonsignori et al., 2012, Falkowska et al., 2012, Scheid et al., 2011, Chuang et al., 2013,
Walker et al., 2009, Liao et al., 2013, Walker et al., 2011). A total of 18 indels were found in
the 11 antibodies. For a given antibody, the distance between an insertion and the
corresponding antigen was computed as the minimum heavy-atom (C, N, O, and S) distance
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between any residue part of the insertion and any residue/glycan part of the antigen.
Similarly, the distance between an antibody deletion and the corresponding antigen was
computed as the minimum heavy-atom distance between either residue flanking the deletion
and any residue/glycan part of the antigen. For a given antibody, loop residues were defined
by the loop, bend, and turn categories in DSSP(Kabsch and Sander, 1983), with distances
computed as the minimum heavy-atom distance between each loop residue and any residue/
glycan in the corresponding antigen. In the above analysis, missing residues in the input
structure were ignored.
Surface plasmon resonance (SPR) affinity and kinetics measurements—
Binding Kd and rate constant (association rate ka, dissociation rate kd) measurements of
recombinant mAbs of VRC-CH30-34 clonal lineage to A244 Δ11 gp120(Liao et al., 2013,
Alam et al., 2013) were carried out on BIAcore 3000 instruments as described
previously(Alam et al., 2011, Alam et al., 2007, Alam et al., 2008). All data analysis was
performed using the BIAevaluation 4.1 analysis software (GE Healthcare).
Neutralization assays—Neutralizing antibody assays in TZM-bl cells were performed as
described previously(Montefiori, 2005). Neutralizing activity of plasma samples in 8 serial
3-fold dilutions starting at 1:20 dilution and for recombinant mAbs in 8 serial 3-fold
dilutions starting at 50ug/ml were tested against autologous and heterologous HIV-1 Env-
pseudotyped viruses in TZM-bl-based neutralization assays using the methods as
described(Montefiori, 2005),(Seaman et al., 2010). The data were calculated as a reduction
in luminescence units compared with control wells and reported as IC50 in μg/ml for mAbs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This study was supported by the National Institutes of Allergy and Infectious Diseases and by intramural NIH
support for the NIAID Vaccine Research Center, by grants from the NIH, NIAID, AI068501 (the Center for HIV/
AIDS Vaccine Immunology),AI100645 (the Center for Vaccine Immunology-Immunogen Discovery) and
HHSN272201000053C (Multiscale Systems Immunology). The authors acknowledge the contributions of the
Center for HIV/AIDS Vaccine Discovery (CHAVI) Clinical Core Team at Chapel Hill, North Carolina (Joe Eron);
Blantyre, Malawi (Johnstone Kumwenda, Taha Taha); Lilongwe, Malawi (Irving Hoffman, Gift Kaminga);
Johannesburg, South Africa (Helen Rees); Moshi, Tanzania (Sam Noel, Saidi Kapiga, John Crump); London, UK
(Sarah Fidler). The authors thank Haiyan Chen, Melissa Cooper, Shi-Mao Xia and Julie Blinn for expert technical
assistance.
T.B.K. designed the indel studies, performed antibody gene sequence analyses and other statistical analyses, wrote
and edited the paper. H.X.L. produced recombinant antibodies and HIV-1 Envs, designed assays, analyzed data,
wrote and edited the paper; S.M.L. performed SPR analysis; R.B. assisted with antibody gene sequence analysis;
R.R.Z. isolated and produced antibodies; S.S. and K.A. performed SPR assays; R.P., K.E.L., C.S. performed
immunoassays; J.P., E.S., E.F performed antibody and HIV-1 Env production; L.M., S.S.A.K. and M.S.C. provided
PBMC samples of HIV-1 infected bnAb individuals; G.K. contributed to the design of the experiments; E.W.
carried out influenza vaccination and sample collection from influenza vaccinees; M.A.M. performed single plasma
cell sorting for isolation of VHDJH and VLJL genes from healthy blood donors and influenza vaccinees; X.W.
isolated VRC-CH30-34 bnAbs, H.R.A-T., I.S.G., and P.D.K., perform the structure analysis, S.D.B. and A.Z.F
performed HTS; J.R.M. isolated antibodies, designed assays, analyzed data, and edited the paper; B.F.H. designed
and directed the immunologic and clinical studies, directed the overall study, analyzed data, and wrote and edited
the paper.
Kepler et al. Page 10























ALAM SM, LIAO HX, DENNISON SM, JAEGER F, PARKS R, ANASTI K, FOULGER A,
DONATHAN M, LUCAS J, VERKOCZY L, NICELY N, TOMARAS GD, KELSOE G, CHEN B,
KEPLER TB, HAYNES BF. Differential reactivity of germ line allelic variants of a broadly
neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol. 2011; 85:11725–
31. [PubMed: 21917975]
ALAM SM, LIAO HX, TOMARAS GD, BONSIGNORI M, TSAO CY, HWANG KK, CHEN H,
LLOYD KE, BOWMAN C, SUTHERLAND L, JEFFRIES TL JR. KOZINK DM, STEWART S,
ANASTI K, JAEGER FH, PARKS R, YATES NL, OVERMAN RG, SINANGIL F, BERMAN
PW, PITISUTTITHUM P, KAEWKUNGWAL J, NITAYAPHAN S, KARASAVVA N, RERKS-
NGARM S, KIM JH, MICHAEL NL, ZOLLA-PAZNER S, SANTRA S, LETVIN NL,
HARRISON SC, HAYNES BF. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX
clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol. 2013; 87:1554–
68. [PubMed: 23175357]
ALAM SM, MCADAMS M, BOREN D, RAK M, SCEARCE RM, GAO F, CAMACHO ZT,
GEWIRTH D, KELSOE G, CHEN P, HAYNES BF. The role of antibody polyspecificity and lipid
reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5
and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol. 2007; 178:4424–
35. [PubMed: 17372000]
ALAM SM, SCEARCE RM, PARKS RJ, PLONK K, PLONK SG, SUTHERLAND LL, GORNY
MK, ZOLLA-PAZNER S, VANLEEUWEN S, MOODY MA, XIA SM, MONTEFIORI DC,
TOMARAS GD, WEINHOLD KJ, KARIM SA, HICKS CB, LIAO HX, ROBINSON J, SHAW
GM, HAYNES BF. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane
proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute
infection. J Virol. 2008; 82:115–25. [PubMed: 17942537]
BONSIGNORI M, HWANG KK, CHEN X, TSAO CY, MORRIS L, GRAY E, MARSHALL DJ,
CRUMP JA, KAPIGA SH, SAM NE, SINANGIL F, PANCERA M, YONGPING Y, ZHANG B,
ZHU J, KWONG PD, O’DELL S, MASCOLA JR, WU L, NABEL GJ, PHOGAT S, SEAMAN
MS, WHITESIDES JF, MOODY MA, KELSOE G, YANG X, SODROSKI J, SHAW GM,
MONTEFIORI DC, KEPLER TB, TOMARAS GD, ALAM SM, LIAO HX, HAYNES BF.
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly
neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011; 85:9998–
10009. [PubMed: 21795340]
BONSIGNORI M, MONTEFIORI DC, WU X, CHEN X, HWANG KK, TSAO CY, KOZINK DM,
PARKS RJ, TOMARAS GD, CRUMP JA, KAPIGA SH, SAM NE, KWONG PD, KEPLER TB,
LIAO HX, MASCOLA JR, HAYNES BF. Two distinct broadly neutralizing antibody specificities
of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J
Virol. 2012; 86:4688–92. [PubMed: 22301150]
BOYD SD, MARSHALL EL, MERKER JD, MANIAR JM, ZHANG LN, SAHAF B, JONES CD,
SIMEN BB, HANCZARUK B, NGUYEN KD, NADEAU KC, EGHOLM M, MIKLOS DB,
ZEHNDER JL, FIRE AZ. Measurement and clinical monitoring of human lymphocyte clonality by
massively parallel VDJ pyrosequencing. Sci Transl Med. 2009; 1:12ra23.
BRINEY BS, WILLIS JR, CROWE JE JR. Location and length distribution of somatic hypermutation-
associated DNA insertions and deletions reveals regions of antibody structural plasticity. Genes and
Immunity. 2012; 13:523. [PubMed: 22717702]
CHUANG GY, ACHARYA P, SCHMIDT SD, YANG Y, LOUDER MK, ZHOU T, KWON YD,
PANCERA M, BAILER RT, DORIA-ROSE NA, NUSSENZWEIG MC, MASCOLA JR, KWONG
PD, GEORGIEV IS. Residue-Level Prediction of HIV-1 Antibody Epitopes Based on
Neutralization of Diverse Viral Strains. J Virol. 2013
EICHLER EE. Masquerading Repeats: Paralogous Pitfalls of the Human Genome. Genome Research.
1998; 8:758–762. [PubMed: 9724321]
FALKOWSKA E, RAMOS A, FENG Y, ZHOU T, MOQUIN S, WALKER LM, WU X, SEAMAN
MS, WRIN T, KWONG PD, WYATT RT, MASCOLA JR, POIGNARD P, BURTON DR.
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does
Kepler et al. Page 11






















not induce conformational changes characteristic of CD4. Journal of virology. 2012; 86:4394–
4403. [PubMed: 22345481]
FUKITA Y, JACOBS H, RAJEWSKY K. Somatic Hypermutation in the Heavy Chain Locus
Correlates with Transcription. Immunity. 1998; 9:105–114. [PubMed: 9697840]
GOTOH O. Optimal sequence alignment allowing for long gaps. Bulletin of Mathematical Biology.
1990; 52:359–373. [PubMed: 2165832]
HAYNES BF, FLEMING J, ST CLAIR EW, KATINGER H, STIEGLER G, KUNERT R,
ROBINSON J, SCEARCE RM, PLONK K, STAATS HF, ORTEL TL, LIAO HX, ALAM SM.
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science.
2005; 308:1906–8. [PubMed: 15860590]
HAYNES BF, KELSOE G, HARRISON SC, KEPLER TB. B-cell-lineage immunogen design in
vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012; 30:423–33. [PubMed:
22565972]
HAYNES BF, MOODY MA, LIAO HX, VERKOCZY L, TOMARAS GD. B cell responses to HIV-1
infection and vaccination: pathways to preventing infection. Trends Mol Med. 2011; 17:108–16.
[PubMed: 21112250]
HRABER P, SEAMAN MS, BAILER RT, MASCOLA JR, MONTEFIORI DC, KORBER BT.
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS.
2014; 28:163–169. 10.1097/QAD.0000000000000106. [PubMed: 24361678]
KABSCH W, SANDER C. Dictionary of protein secondary structure: Pattern recognition of hydrogen-
bonded and geometrical features. Biopolymers. 1983; 22:2577–2637. [PubMed: 6667333]
KEPLER TB. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors.
F1000Res. 2013; 2:103. [PubMed: 24555054]
KEPLER TB, MUNSHAW S, WIEHE K, ZHANG R, YU JS, WOODS CW, DENNY TN,
TOMARAS GD, ALAM SM, MOODY MA, KELSOE G, LIAO HX, HAYNES BF.
Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Front
Immunol. 2014; 5:170. [PubMed: 24795717]
KRAUSE JC, EKIERT DC, TUMPEY TM, SMITH PB, WILSON IA, CROWE JE. An Insertion
Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human
Antibody. mBio. 2011:2.
KWONG PD, MASCOLA JR. Human antibodies that neutralize HIV-1: identification, structures, and
B cell ontogenies. Immunity. 2012; 37:412–25. [PubMed: 22999947]
LIAO HX, BONSIGNORI M, ALAM SM, MCLELLAN JS, TOMARAS GD, MOODY MA,
KOZINK DM, HWANG KK, CHEN X, TSAO CY, LIU P, LU X, PARKS RJ, MONTEFIORI
DC, FERRARI G, POLLARA J, RAO M, PEACHMAN KK, SANTRA S, LETVIN NL,
KARASAVVAS N, YANG ZY, DAI K, PANCERA M, GORMAN J, WIEHE K, NICELY NI,
RERKS-NGARM S, NITAYAPHAN S, KAEWKUNGWAL J, PITISUTTITHUM P,
TARTAGLIA J, SINANGIL F, KIM JH, MICHAEL NL, KEPLER TB, KWONG PD,
MASCOLA JR, NABEL GJ, PINTER A, ZOLLA-PAZNER S, HAYNES BF. Vaccine induction
of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope
protein variable regions 1 and 2. Immunity. 2013; 38:176–86. [PubMed: 23313589]
LIAO HX, CHEN X, MUNSHAW S, ZHANG R, MARSHALL DJ, VANDERGRIFT N,
WHITESIDES JF, LU X, YU JS, HWANG KK, GAO F, MARKOWITZ M, HEATH SL, BAR
KJ, GOEPFERT PA, MONTEFIORI DC, SHAW GC, ALAM SM, MARGOLIS DM, DENNY
TN, BOYD SD, MARSHAL E, EGHOLM M, SIMEN BB, HANCZARUK B, FIRE AZ, VOSS
G, KELSOE G, TOMARAS GD, MOODY MA, KEPLER TB, HAYNES BF. Initial antibodies
binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp
Med. 2011; 208:2237–49. [PubMed: 21987658]
LIAO HX, LEVESQUE MC, NAGEL A, DIXON A, ZHANG R, WALTER E, PARKS R,
WHITESIDES J, MARSHALL DJ, HWANG KK, YANG Y, CHEN X, GAO F, MUNSHAW S,
KEPLER TB, DENNY T, MOODY MA, HAYNES BF. High-throughput isolation of
immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J
Virol Methods. 2009; 158:171–9. [PubMed: 19428587]
MASCOLA JR, HAYNES BF. HIV-1 neutralizing antibodies: understanding nature’s pathways.
Immunological Reviews. 2013; 254:225–244. [PubMed: 23772623]
Kepler et al. Page 12






















MONTEFIORI DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase
reporter gene assays. Curr Protoc Immunol. 2005 Chapter 12. Unit 12 11.
MOODY MA, ZHANG R, WALTER EB, WOODS CW, GINSBURG GS, MCCLAIN MT, DENNY
TN, CHEN X, MUNSHAW S, MARSHALL DJ, WHITESIDES JF, DRINKER MS, AMOS JD,
GURLEY TC, EUDAILEY JA, FOULGER A, DEROSA KR, PARKS R, MEYERHOFF RR, YU
JS, KOZINK DM, BAREFOOT BE, RAMSBURG EA, KHURANA S, GOLDING H,
VANDERGRIFT NA, ALAM SM, TOMARAS GD, KEPLER TB, KELSOE G, LIAO HX,
HAYNES BF. H3N2 influenza infection elicits more cross-reactive and less clonally expanded
anti-hemagglutinin antibodies than influenza vaccination. PLoS One. 2011; 6:e25797. [PubMed:
22039424]
MOORE PL, GRAY ES, SHEWARD D, MADIGA M, RANCHOBE N, LAI Z, HONNEN WJ,
NONYANE M, TUMBA N, HERMANUS T, SIBEKO S, MLISANA K, ABDOOL KARIM SS,
WILLIAMSON C, PINTER A, MORRIS L, STUDY ATC. Potent and Broad Neutralization of
HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the
V2 Loop. Journal of Virology. 2011; 85:3128–3141. [PubMed: 21270156]
MORRIS L, CHEN X, ALAM M, TOMARAS G, ZHANG R, MARSHALL DJ, CHEN B, PARKS R,
FOULGER A, JAEGER F, DONATHAN M, BILSKA M, GRAY ES, ABDOOL KARIM SS,
KEPLER TB, WHITESIDES J, MONTEFIORI D, MOODY MA, LIAO H-X, HAYNES BF.
Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by
Antigen-Specific Single B Cell Sorting. PLoS ONE. 2011; 6:e23532. [PubMed: 21980336]
MOUQUET H, NUSSENZWEIG MC. Polyreactive antibodies in adaptive immune responses to
viruses. Cell Mol Life Sci. 2012; 69:1435–45. [PubMed: 22045557]
PEJCHAL R, DOORES KJ, WALKER LM, KHAYAT R, HUANG P-S, WANG S-K, STANFIELD
RL, JULIEN J-P, RAMOS A, CRISPIN M, DEPETRIS R, KATPALLY U, MAROZSAN A,
CUPO A, MALOVESTE S, LIU Y, MCBRIDE R, ITO Y, SANDERS RW, OGOHARA C,
PAULSON JC, FEIZI T, SCANLAN CN, WONG C-H, MOORE JP, OLSON WC, WARD AB,
POIGNARD P, SCHIEF WR, BURTON DR, WILSON IA. A Potent and Broad Neutralizing
Antibody Recognizes and Penetrates the HIV Glycan Shield. Science. 2011; 334:1097–1103.
[PubMed: 21998254]
SCHEID JF, MOUQUET H, UEBERHEIDE B, DISKIN R, KLEIN F, OLIVERA TY, PIETZSCH J,
FENYO D, ABADIR A, VELINZON K, HURLEY A, MYUNG S, BOULAD F, POIGNARD P,
BURTON D, PEREYRA F, HO DD, WALKER BD, SEAMAN MS, BJORKMAN PJ, CHAIT
BT, NUSSENZWEIG MC. Sequence and Structural Convergence of Broad and Potent HIV
Antibodies That Mimic CD4 Binding. Science. 2011; 333:633–7. [PubMed: 21798951]
SEAMAN MS, JANES H, HAWKINS N, GRANDPRE LE, DEVOY C, GIRI A, COFFEY RT,
HARRIS L, WOOD B, DANIELS MG, BHATTACHARYA T, LAPEDES A, POLONIS VR,
MCCUTCHAN FE, GILBERT PB, SELF SG, KORBER BT, MONTEFIORI DC, MASCOLA
JR. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of
neutralizing antibodies. J Virol. 2010; 84:1439–52. [PubMed: 19939925]
SHEN X, PARKS RJ, MONTEFIORI DC, KIRCHHERR JL, KEELE BF, DECKER JM,
BLATTNER WA, GAO F, WEINHOLD KJ, HICKS CB, GREENBERG ML, HAHN BH, SHAW
GM, HAYNES BF, TOMARAS GD. In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal
Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth.
Journal of Virology. 2009; 83:3617–3625. [PubMed: 19193787]
SMITH D, CREADON G, JENA P, PORTANOVA J, KOTZIN B, WYSOCKI L. Di- and
trinucleotide target preferences of somatic mutagenesis in normal and autoreactive B cells. The
Journal of Immunology. 1996; 156:2642–2652. [PubMed: 8786330]
TOMARAS GD, BINLEY JM, GRAY ES, CROOKS ET, OSAWA K, MOORE PL, TUMBA N,
TONG T, SHEN X, YATES NL, DECKER J, WIBMER CK, GAO F, ALAM SM,
EASTERBROOK P, ABDOOL KARIM S, KAMANGA G, CRUMP JA, COHEN M, SHAW
GM, MASCOLA JR, HAYNES BF, MONTEFIORI DC, MORRIS L. Polyclonal B Cell
Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals.
Journal of Virology. 2011; 85:11502–11519. [PubMed: 21849452]
Kepler et al. Page 13






















VERKOCZY L, KELSOE G, MOODY MA, HAYNES BF. Role of immune mechanisms in induction
of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol. 2011; 23:383–90. [PubMed:
21524897]
WALKER LM, HUBER M, DOORES KJ, FALKOWSKA E, PEJCHAL R, JULIEN J-P, WANG S-
K, RAMOS A, CHAN-HUI PY, MOYLE M, MITCHAM JL, HAMMOND PW, OLSEN OA,
PHUNG P, FLING S, WONG C-H, PHOGAT S, WRIN T, SIMEK M, INVESTIGATOR P,
KOFF WC, WILSON MJ, BURTON D, POIGNARD P, PHOGAT SK, CHAN-HUI PY,
WAGNER D, PHUNG P, GOSS JL, WRIN T, SIMEK MD, FLING S, MITCHAM JL,
LEHRMAN JK, PRIDDY FH, OLSEN OA, FREY SM, HAMMOND PW, KAMINSKY S,
ZAMB T, MOYLE M, KOFF WC, POIGNARD P, BURTON DR. Broad neutralization covarage
of HIV by multiple highly potent antibodies. Nature. 2011; 477:466–470. [PubMed: 21849977]
WALKER LM, PHOGAT SK, CHAN-HUI P-Y, WAGNER D, PHUNG P, GOSS JL, WRIN T,
SIMEK MD, FLING S, MITCHAM JL, LEHRMAN JK, PRIDDY FH, OLSEN OA, FREY SM,
HAMMOND PW, INVESTIGATORS PGP, KAMINSKY S, ZAMB T, MOYLE M, KOFF WC,
POIGNARD P, BURTON DR. Broad and Potent Neutralizing Antibodies from an African Donor
Reveal a New HIV-1 Vaccine Target. Science. 2009; 326:285–289. [PubMed: 19729618]
WANG C, LIU Y, XU LT, JACKSON KJL, ROSKIN KM, PHAM TD, LASERSON J, MARSHALL
EL, SEO K, LEE J-Y, FURMAN D, KOLLER D, DEKKER CL, DAVIS MM, FIRE AZ, BOYD
SD. Effects of Aging, Cytomegalovirus Infection, and EBV Infection on Human B Cell
Repertoires. The Journal of Immunology. 2014; 192:603–611. [PubMed: 24337376]
WILSON PC, BOUTEILLER OD, LIU Y-J, POTTER K, BANCHEREAU J, CAPRA JD, PASCUAL
V. Somatic Hypermutation Introduces Insertions and Deletions into Immunoglobulin V Genes.
The Journal of Experimental Medicine. 1998; 187:59–70. [PubMed: 9419211]
WRAMMERT J, SMITH K, MILLER J, LANGLEY WA, KOKKO K, LARSEN C, ZHENG NY,
MAYS I, GARMAN L, HELMS C, JAMES J, AIR GM, CAPRA JD, AHMED R, WILSON PC.
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;
453:667–71. [PubMed: 18449194]
WU X, YANG ZY, LI Y, HOGERKORP CM, SCHIEF WR, SEAMAN MS, ZHOU T, SCHMIDT
SD, WU L, XU L, LONGO NS, MCKEE K, O’DELL S, LOUDER MK, WYCUFF DL, FENG Y,
NASON M, DORIA-ROSE N, CONNORS M, KWONG PD, ROEDERER M, WYATT RT,
NABEL GJ, MASCOLA JR. Rational design of envelope identifies broadly neutralizing human
monoclonal antibodies to HIV-1. Science. 2010; 329:856–61. [PubMed: 20616233]
WU X, ZHOU T, ZHU J, ZHANG B, GEORGIEV I, WANG C, CHEN X, LONGO NS, LOUDER M,
MCKEE K, O’DELL S, PERFETTO S, SCHMIDT SD, SHI W, WU L, YANG Y, YANG Z-Y,
YANG Z, ZHANG Z, BONSIGNORI M, CRUMP JA, KAPIGA SH, SAM NE, HAYNES BF,
SIMEK M, BURTON DR, KOFF WC, DORIA-ROSE NA, CONNORS M, PROGRAM NCS,
MULLIKIN JC, NABEL GJ, ROEDERER M, SHAPIRO L, KWONG PD, MASCOLA JR.
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep
Sequencing. Science. 2011; 333:1593–1602. [PubMed: 21835983]
ZHOU T, GEORGIEV I, WU X, YANG Z-Y, DAI K, FINZI A, DO KWON Y, SCHEID JF, SHI W,
XU L, YANG Y, ZHU J, NUSSENZWEIG MC, SODROSKI J, SHAPIRO L, NABEL GJ,
MASCOLA JR, KWONG PD. Structural Basis for Broad and Potent Neutralization of HIV-1 by
Antibody VRC01. Science. 2010; 329:811–817. [PubMed: 20616231]
ZHOU T, ZHU J, WU X, MOQUIN S, ZHANG B, ACHARYA P, GEORGIEV IVELINS, ALTAE-
TRAN HANR, CHUANG G-Y, JOYCE MG, DO KWON Y, LONGO NANCYS, LOUDER
MARKK, LUONGO T, MCKEE K, SCHRAMM CHAIMA, SKINNER J, YANG Y, YANG Z,
ZHANG Z, ZHENG A, BONSIGNORI M, HAYNES BARTONF, SCHEID JOHANNESF,
NUSSENZWEIG MICHELC, SIMEK M, BURTON DENNISR, KOFF WAYNEC, MULLIKIN
JAMESC, CONNORS M, SHAPIRO L, NABEL GARYJ, MASCOLA JOHNR, KWONG
PETERD. Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and
Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity. 2013
Kepler et al. Page 14























• Indels are frequent among HIV-1 broad neutralizing antibodies (bnAbs)
• Indel occurrence depends solely on the frequency of somatic hypermutation.
• Indels in HIV-1 bnAbs are proximal to antigen binding sites.
• A compound indel in a CD4-binding site bnAb is required for activity.
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Figure 1. Comparison of VH mutation frequencies in HIV-1 bnAbs with those in other
antibodies
Box plots showing centered log frequencies (cyan) for in-frame insertions (a) and deletions
(b) per 105 VH bases in potentially functional heavy chain genes; and insertion and deletion
log frequency residuals (blue) after subtracting log frequency predicted from substitution
frequency alone. Subject classifications: Subjects known to produce broadly neutralizing
antibodies against HIV-1 (bnAb), subjects who had been vaccinated against influenza one
week prior to sampling (influenza vaccinee), HIV-1 infected subjects who had not produced
bnAbs by the time of this study (HIV no bnAb), and uninfected controls (control). Boxes
cover from the first to the third quartiles; whiskers extend to the standard span—1.5 times
the interquartile range. Cyan boxes were centered by subtracting the mean frequency over
all subjects; blue boxes were not centered. c: Log of the insertion frequency per 105 bases
(c) and deletion frequency (d) as a function of the log of the substitution frequency per base.
The colored line segments show the linear regression for each of the subject classifications;
the gray line segment shows the linear regression for all subjects at once.
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Time course of in-frame insertion (a) and deletion (b) frequencies in days post-infection for
HIV-infected subjects. The five subjects known to produce bnAbs are indicated with solid
lines; the four who have not made bnAbs are indicated with dashed lines. Only subjects with
samples taken at three or more times were included.
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Figure 3. Structural analysis of antibody indels
a and b, Distribution of distances between antigen and: indels (a) or loop residues (b). These
distributions are statistically distinguishable (p < 0.0001, Mann-Whitney test). Distances are
shown as bins in 5 Å increments. (c-e) Location of insertions and deletions in antigen-bound
structures of antibodies VRC-CH31 (c), VRC01 (d), 3BNC117 (e), and PGT128 (f).
Structures are shown in ribbon representation with antibody heavy chains in green, light
chains in blue, and the respective antigens in grey. For PGT128, antibody-interacting
glycans on antigen are shown as grey sticks. The regions where insertions and deletions
were observed are highlighted in yellow and red, respectively. See also Figure S1.
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Figure 4. Maturation pathway of CD4BS bnAb
CH31 clonal lineage. a, Alignment of the observed CD4BS bnAb CH31, and observed
CH31 clonally related VHDJH sequences from HTS shows the likely duplication and
deletion events leading to the mature antibody. An AID hot spot “AGC” at alignment
position 162 (red line segment) appears as a result of nucleotide substitution in 2GNM7S.
Dots indicate identity with the nucleotides in the UCA; dashes represent gaps. Shading of
the sequences corresponds to the schematic deconstruction in part b. b, A schematic showing
the structures of the observed heavy chains (2GNM7S, 2H162G) in terms of the sequence
elements A, A’; D0, D1, D2, and B, and the artificial constructs made by inserting and
deleting the duplicons. c, A maximum-likelihood tree incorporating all antibody members
(CH30-34) of the CH31 clonal lineage VHDJH_ and the VHDJH isolated by HTS. The
VHDJH genes indicated in blue boxes have been synthesized and paired with intermediate-4
light chain for production of recombinant monoclonal antibodies for testing the binding and
neutralizing activity. The compound insertion-deletion event occurred on the branch
indicated by the red asterisk. The asterisks on the sequence titles 2H4SHE and 2G9LMX
indicate that each of these sequences has hundreds (**) or tens (*) of closely-related
sequences not shown on the tree.
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Figure 5. SPR-estimated kinetic rate constants
a, association rate, ka. b, dissociation rate, kd for the tested antibodies as a function of
evolutionary distance (expected nucleotide changes per base) from the inferred unmutated
common ancestor (UCA). Solid line segments indicate clonal descent. Dashed line segments
indicate artificial descent by insertion or deletion of the respective duplicon. c, The
estimated dissociation, Kd (the ratio of the on-rate to the off-rate, Kd = kd/ka) vs. the
evolutionary distance from the UCA.
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Table 1
Insertions and Deletions in broadly neutralizing anti-HIV-1 antibodies.
Antibody Indel Type Length (aa) Location
CAP206-CH12 Deletion 3 HFR3
NIH45-46 Deletion 6 LCDR1
HJ16 Deletion 3 HCDR2
HJ16 Insertion 3 LFR3
VRC01 Deletion 6 LCDR1
VRC03 Insertion 21 HFR3
CH98 Deletion 15 LFR1
CL103 Deletion 9 LFR1
PGT121-3 Insertion 9 LFR3
PGT125-8 Insertion 18 HCDR2
PGT125-8 Deletion 15 LCDR1
PGT136 Insertion 3 HCDR2
PGT135-7 Insertion 15 HCDR1
PGT135-7 Insertion 3 LFR1
PGT145 Deletion 3 HCDR3
PG9 Insertion 3 HFR1
CH30-34 Insertion 27 HCDR1
3BNC117, 3BNC60 Insertion 12 HFR3
3BNC117, 3BNC60 Deletion 12 LCDR1
8ANC131, 8ANC134 Deletion 3 HCDR2
8ANC131, 8ANC135 Deletion 3 LCDR1
8ANC195 Deletion 3 HCDR1
8ANC195 Insertion 15 HCDR2
8ANC195 Insertion 3 LCDR1
VRCPG04,04B Deletion 9 LCRD1
VRCPG04,04B Insertion 3 HCDR1
VRCPG04,04B Insertion 3 HFR3
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Table 2
Neutralization of HIV-1 tier 1 and 2 isolates by members of CD4BS bnAb CH31 clonal lineage.
TCID50, ug/ml
HIV-1 isolates Control
Antibody B.MN.3 C.MW965 B.SF162 B.W61D C.C3347 C.DU172 A.Q23 A.TRO.11 MuLV
UCA >50 >50 >50 >50 >50 >50 >50 >50 >50
2FNGT3 >50 >50 >50 >50 >50 >50 >50 >50 >50
2JSKAU >50 >50 >50 >50 >50 >50 1.51 >50 >50
2GNM7S 30.1 >50 >50 >50 >50 >50 6.57 >50 >50
2H162G 0.03 6.78 1.07 2.62 10.4 5.61 0.08 0.94 >50
2H4SHE <0.023 2.45 0.402 0.023 3.86 1.63 0.085 0.75 >50
2G9LMX <0.023 1.43 0.443 0.326 6.48 7.7 0.07 0.95 >50
I1 3.86 10.2 1.34 >50 0.98 0.91 <0.23 0.46 >50
I2 7.19 15.8 1.68 >50 0.77 1.03 <0.23 0.54 >50
I3 5.55 9.09 1.12 >50 0.46 0.71 <0.23 0.47 >50
I4 2.26 5.38 0.77 >50 0.34 0.61 <0.23 0.33 >50
CH31 0.0225 0.993 0.121 8.34 0.17 1.15 <023 0.15 >50
2H162G − D1 >50 >50 >50 >50 >50 >50 3.19 >50 >50
2GNM7S+D.1 14.3 >50 49.7 38.3 >50 >50 4.21 >50 >50
2GNM7S+D2 16.2 >50 27.4 5.8 >50 >50 25.0 >50 >50
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